Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.96 |
| ▸ | MEN1 | O00255 | 8/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.96 |
| ▸ | HBB | P68871 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.93 |
| ▸ | USP2 | O75604 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | DRD2 | P14416 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL453934 | 1.00 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL5973732 | 1.00 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL14687482 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL28796595 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL26499 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL215655 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL19357 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL29392321 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL302506 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL6661856 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412775-A2 | SOLDER ADHESIVE AND A PRODUCTION METHOD FOR THE SAME, AND AN ELECTRONIC DEVICE COMPRISING THE SAME | Duksan Hi-Metal Co., Ltd. (KR) | 2012-02-01 | — | — | EP | claimed |
| US-6086738-A | FORMING CHARACTERS AND IMAGES ON A CYLINDER AS A POSITIVE ELECTRODE WITH AN INK WHICH BRINGS ABOUT COLORED-COAGULATED COLLOID WITH ELECTRIC CHARGE, TRANSFERRING THE CHARACTERS AND IMAGES TO THE RECORD SHEET | TOKUSHO PAPER MFG. CO. LTD. (JP) | 2000-07-11 | — | — | US | claimed |
| EP-0776768-B1 | Record sheet used in electrocoagulation printing method | TOKUSHU PAPER MFG CO LTD (JP) | 2000-03-01 | — | — | EP | claimed |
| EP-0776768-A2 | Record sheet used in electrocoagulation printing method | TOKUSHU PAPER MFG. CO., LTD (JP) | 1997-06-04 | — | — | EP | claimed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4292820-A1 | INK SET FOR INKJET RECORDING, INKJET RECORDING METHOD, MAINTENANCE METHOD, AND INKJET RECORDING APPARATUS | KONICA MINOLTA, INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3363644-B1 | RECORDING METHOD AND RECORDING APPARATUS | SEIKO EPSON CORP (JP) | 2023-05-03 | — | — | EP | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-3375828-B1 | INK JET RECORDING METHOD AND INK SET | SEIKO EPSON CORP (JP) | 2021-02-24 | — | — | EP | disclosed |
| US-10907065-B2 | Ink jet recording method and ink set | SEIKO EPSON CORPORATION | 2021-02-02 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-4518774-A | CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-21 | — | — | US | disclosed |
| US-4500461-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-02-19 | — | — | US | disclosed |
| US-4379922-A | CHEMICAL INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-04-12 | — | — | US | disclosed |
| EP-0048504-A2 | Intermediate compounds for preparing cephem compounds; processes for their preparation and processes for preparing cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
| US-4298529-A | INTERMEDIATES FOR USEFUL CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-03 | — | — | US | disclosed |
| EP-0009671-A2 | Starting compounds for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
| US-4103082-A | ANTIMICROBIAL | SUAMI T | 1978-07-25 | — | — | US | disclosed |
| US-4057561-A | OVULATION INHIBITOR, ANDROGENIC, ANABOLIC | HOFFMANN-LA ROCHE INC. (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | MAPT 301/4885MEN1 457/4885KMT2A 2579/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | MAPT 301/4885MEN1 457/4885KMT2A 2579/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | MAPT 301/4885MEN1 457/4885KMT2A 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.